---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-008028"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2022-11-23T23:59:59+00:00"
generated_at: "2026-06-21T13:26:01.319589+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health receives $313,709 R&D rebate from Australian government for Phase I trial work

## Summary
- Rebate of $313,709 ($468,727 AUD) received on November 18, 2022.
- Funds are for clinical work conducted in Australia during fiscal year ended July 31, 2022.
- Rebate relates to the Company's Phase I human clinical trial expenses.

## SEC filing metadata
- accession: 0001683168-22-008028
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2022-11-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316822008028/0001683168-22-008028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316822008028/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-008028
- JSON: https://secwatch.observer/filing/0001683168-22-008028.json
- Plain text: https://secwatch.observer/filing/0001683168-22-008028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.